High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 24352348.
- Also identified by DOI 10.1093/cid/cit933 and PMC identifier 3952602.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
In a randomized comparison of nevirapine or abacavir with zidovudine plus lamivudine, routine viral load monitoring was not performed, yet 27% of individuals with viral failure at week 48 experienced resuppression by week 96 without switching. This supports World Health Organization recommendations that suspected viral failure should trigger adherence counseling and repeat measurement before a treatment switch is considered.
Medical subject headings
- Anti-HIV Agents
- Lamivudine
- Zidovudine